Dan Li
Directeur/Membre du Conseil chez ZHONGCHAO INC.
Fortune : 2 682 $ au 30/04/2024
Profil
Dan Li is an Independent Director at Zhongchao, Inc. since 2019.
Previously, she worked as a Manager-Medicine Management Department at EPS Holdings, Inc. from 2009 to 2011.
Dr. Li holds a doctorate degree from Keio University, a graduate degree from Peking University, and an undergraduate degree from North China University of Science & Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ZHONGCHAO, INC. CLASS A
0,09% | 11/05/2023 | 1 800 ( 0,09% ) | 2 682 $ | 30/04/2024 |
Postes actifs de Dan Li
| Sociétés | Poste | Début |
|---|---|---|
| ZHONGCHAO INC. | Directeur/Membre du Conseil | 06/08/2019 |
Anciens postes connus de Dan Li
| Sociétés | Poste | Fin |
|---|---|---|
| EPS HOLDINGS, INC. | Corporate Officer/Principal | 01/11/2011 |
Formation de Dan Li
| North China University of Science & Technology | Undergraduate Degree |
| Peking University | Graduate Degree |
| Keio University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ZHONGCHAO INC. | Commercial Services |
| Entreprise privées | 1 |
|---|---|
EPS Holdings, Inc.
 EPS Holdings, Inc. BiotechnologyHealth Technology EPS Holdings, Inc. engages in the drug development business. It operates through the following segments: Contract Research Organization (CRO), Site Management Organization (SMO), Contract Sales Organization (CSO), Global Research, Ekishin, and Others. The CRO segment offers clinical trials, data management, and statistical analysis. The SMO segment enters into contracts with medical institutions to conduct clinical trials. The CSO segment provides drug information and awareness for medical and pharmaceutical industries. The Global Research segment provides consignment services through its subsidiary for multilateral clinical trials in Asia-Pacific. The Ekishin segment focuses on medical equipment, pharmaceutical and investment related businesses through its Japan and China based subsidiaries. The Others segment provides various services related to management of clinical research from business processing outsource business related to medicine and medical care. The company was founded on May 30, 1991 and is headquartered in Tokyo, Japan. | Health Technology |